Navigation Links
Navilyst Medical Announces Global Debut Today : Former Boston Scientific Business Units Combine to Lead Fluid Management and Vascular Access Markets
Date:8/4/2008

Navilyst Medical, formerly Boston Scientific’s Fluid Management and Vascular Access businesses, today announced its new company name following the February 2008 acquisition by Avista Capital Partners, a private equity firm focused on growth-oriented healthcare, energy and media companies.

MARLBOROUGH, Mass. (Business Wire EON) August 4, 2008 -- "Navilyst Medical combines the best attributes of an established medical device company—market-leading technology, superior clinical data, experienced leadership and proven worldwide sales and distribution capabilities. We maintain the singular focus of a small, eager organization striving to improve patient care while collaborating with clinicians in the global marketplace," said President Dave McClellan.

Navilyst Medical manufactures and markets a portfolio of fluid management and vascular access products used during some of the most frequent hospital procedures including angiography and angioplasty. Navilyst Medical's Fluid Management business, including the proprietary NAMIC line of products enjoys a leading global market share. Navilyst Medical's vascular access products include devices designed to provide access to the blood stream for patients requiring intravenous antibiotics, nutrition, chemotherapy, blood sampling and hemodialysis. The company's PASV Technology, with strong clinical data, is uniquely designed to automatically close after infusion, disconnection or aspiration, and remain closed during normal pressure fluctuations, reducing the risk of complications including catheter-related bloodstream infections.

"At Navilyst Medical we are exclusively dedicated to designing, developing, manufacturing and marketing high quality products that make it possible for lifesaving diagnostics, interventions and drug delivery to occur every day," said Navilyst Medical's McClellan. "We will build upon a strong foundation and look forward to living up to our new name by navigating change and being a catalyst for innovation."

Navilyst Medical employs approximately 800 people, and is headquartered in Marlborough, MA with an ISO-certified manufacturing plant in Glens Falls, NY. Products are distributed in 76 countries and are sold direct in the United States. The company is on track to launch several new products into the global marketplace through internal development and strategic alliances during the upcoming year.

"It is the company's strategic intent to become the first choice provider of medical devices for vascular access, and the diagnosis and treatment of vascular disease. This strong combination of product heritage and experienced employees able to execute on this vision captured Avista's interest in the deal from the outset. By 2011 the company should look very different than we do today—and that's exciting," added Navilyst Medical CEO Ron Sparks.

About Navilyst Medical

Navilyst Medical, headquartered in Marlborough, MA, was formed in February 2008 from Boston Scientific's Fluid Management and Vascular Access business units. Its breakthrough products, including the PASV Valve Technology, Xcela PICC and NAMIC Fluid Management devices, help hospitals create clinical and economic solutions for their patients. The Company distributes its products worldwide and has its lead U.S. manufacturing facility in Glens Falls, NY. For more information, please visit: www.navilystmedical.com.

About Avista Capital Partners

Avista Capital Partners is a leading private equity firm with offices in New York and Houston. Founded in 2005, Avista manages $2.0 billion in private equity capital. Avista's strategy is to make controlling or influential minority investments primarily in growth-oriented media, healthcare and energy companies. Through its team of seasoned investment professionals and industry experts, Avista seeks to invest in and add value to well-positioned businesses with exceptional leadership. For more information, visit http://www.avistacap.com.

FORWARD-LOOKING STATEMENTS: This Release contains forward-looking statements, including statements regarding development of Navilyst Medical's existing and new products, the Company's progress toward commercial growth, and future opportunities. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing, and other risks and challenges. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.

Read the full story at http://www.prweb.com/releases/navilyst/medical/prweb1176824.htm


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved  

Related medicine news :

1. MSU engineering team designs innovative medical device
2. ATS Medical to Present at the 2007 Thomas Weisel Partners Healthcare Conference
3. Providence St. Joseph Medical Center, Caregivers Reach Agreement on a Union Contract
4. Owner and Operator of Florida Durable Medical Equipment Company Convicted of Medicare Fraud
5. Father and Daughter From Tanzania Receive Their First Medical Examination in Newport Beach
6. Doctors and medical ethicist discuss whether doctors should participate in capital punishment
7. Preparation for Natural Disasters Critical for People With Diabetes, Chronic Medical Conditions
8. Doctors and Medical Ethicist Discuss Whether Doctors Should Participate in Capital Punishment
9. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
10. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
11. FDA Seeks to Regulate Complementary and Alternative Medicine; Products Such as Vegetable Juice Could Be Restricted for Medical Use
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
 Navilyst Medical Announces Global Debut Today :  Former Boston Scientific Business Units Combine to Lead Fluid Management and Vascular Access Markets 
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/26/2016)... , ... June 26, 2016 , ... ... once they have been diagnosed with endometriosis. These women need a treatment plan ... require a comprehensive approach that can help for preservation of fertility and ultimately ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Austin residents ... the American College of Mohs Surgery and to Dr. Russell Peckham for medical and ... highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed ...
(Date:6/25/2016)... Viejo, California (PRWEB) , ... June 25, 2016 , ... ... to fit their specific project," said Christina Austin - CEO of Pixel Film Studios. ... fully customizable and all within Final Cut Pro X . Simply select a ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... As a ... Magna Cum Laude and his M.D from the David Geffen School of Medicine at ... returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Research and Markets has announced the addition of the ... offering. The current unmet ... for MedImmune to enter. The US ageing population creates a ... considerable growth for effective anti-influenza medications. The introduction of a ... development is still in its infancy. Key ...
(Date:6/23/2016)... and BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma ... as the company,s second affiliate in Latin America . ... ... Astellas Farma Colombia ... ...
(Date:6/23/2016)... 2016 Research and Markets has ... Global Analysis (United States, China, Japan, Brazil, United Kingdom, ... their offering. Surgical ... business planners, provides surgical procedure volume data in a ... an in-depth analysis of growth drivers and inhibitors, including ...
Breaking Medicine Technology: